Pharmacological Prevention of Ectopic Erythrophagocytosis by Cilostazol Mitigates Ferroptosis in NASH
暂无分享,去创建一个
Y. Yoo | Y. Kim | S. Suh | J. Park | Y. Baek | Kangeun Ko | Woo Young Kwon | S. Han | H. Y. Kim
[1] Y. Yoo,et al. Hepatic STAMP2 alleviates polychlorinated biphenyl‐induced steatosis and hepatic iron overload in NAFLD models , 2022, Environmental toxicology.
[2] Ming Yan,et al. Loss of hepatic Flcn protects against fibrosis and inflammation by activating autophagy pathways , 2021, Scientific Reports.
[3] Y. Birnbaum,et al. Cilostazol: a Review of Basic Mechanisms and Clinical Uses , 2021, Cardiovascular Drugs and Therapy.
[4] Y. Yoo,et al. Hepatic STAMP2 mediates recombinant FGF21‐induced improvement of hepatic iron overload in nonalcoholic fatty liver disease , 2020, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[5] G. Birk,et al. Deep learning enables pathologist-like scoring of NASH models , 2019, Scientific Reports.
[6] J. Bosch,et al. New Rat Model of Advanced NASH Mimicking Pathophysiological Features and Transcriptomic Signature of The Human Disease , 2019, Cells.
[7] T. Greten,et al. The effects of platelet accumulation in fatty liver disease , 2019, Nature Reviews Gastroenterology & Hepatology.
[8] J. Jelsing,et al. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals. , 2019, American journal of physiology. Gastrointestinal and liver physiology.
[9] D. Tang,et al. The release and activity of HMGB1 in ferroptosis. , 2019, Biochemical and biophysical research communications.
[10] Z. Younossi. Non-alcoholic fatty liver disease - A global public health perspective. , 2019, Journal of hepatology.
[11] Caroline L. Wilson,et al. Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer , 2019, Nature Medicine.
[12] Y. Yoo,et al. Cilostazol Improves HFD-Induced Hepatic Steatosis by Upregulating Hepatic STAMP2 Expression through AMPK , 2018, Molecular Pharmacology.
[13] C. McClain,et al. Role of cAMP and phosphodiesterase signaling in liver health and disease. , 2018, Cellular signalling.
[14] N. S. Gowert,et al. Platelet-RBC interaction mediated by FasL/FasR induces procoagulant activity important for thrombosis , 2018, The Journal of clinical investigation.
[15] Hong Chen,et al. Pathogenesis of non-alcoholic fatty liver disease in children and adolescence: From “two hit theory” to “multiple hit model” , 2018, World journal of gastroenterology.
[16] R. Weissleder,et al. On-demand erythrocyte disposal and iron recycling requires transient macrophages in the liver , 2016, Nature Medicine.
[17] D. Tang,et al. Ferroptosis: process and function , 2016, Cell Death and Differentiation.
[18] H. Cortez‐Pinto,et al. Necroptosis is a key pathogenic event in human and experimental murine models of non-alcoholic steatohepatitis. , 2015, Clinical science.
[19] S. Meuth,et al. Platelets induce apoptosis via membrane-bound FasL. , 2015, Blood.
[20] J. Balla,et al. Red blood cell, hemoglobin and heme in the progression of atherosclerosis , 2014, Front. Physiol..
[21] Fernando A Bozza,et al. Platelet Activation and Apoptosis Modulate Monocyte Inflammatory Responses in Dengue , 2014, The Journal of Immunology.
[22] A. Wree,et al. Biomarkers of liver cell death. , 2014, Journal of hepatology.
[23] P. Kubes,et al. Nucleation of platelets with bloodborne pathogens on Kupffer cell precedes other innate immunity and contributes to bacterial clearance , 2013, Nature Immunology.
[24] Kenji Suzuki,et al. A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma , 2013, Medical Molecular Morphology.
[25] M. Garrick,et al. Heme carrier protein 1 transports heme and is involved in heme-Fe metabolism. , 2012, American journal of physiology. Cell physiology.
[26] A. Feldstein,et al. Mean platelet volume as a marker of increased cardiovascular risk in patients with nonalcoholic steatohepatitis , 2012, Hepatology.
[27] L. N. Valenti,et al. Iron in fatty liver and in the metabolic syndrome: a promising therapeutic target. , 2011, Journal of hepatology.
[28] T. Saibara,et al. Platelet count for predicting fibrosis in nonalcoholic fatty liver disease , 2011, Journal of Gastroenterology.
[29] Florian Lang,et al. Erythrocyte programmed cell death , 2008, IUBMB life.
[30] H. Kirikoshi,et al. Effectiveness of antiplatelet drugs against experimental non-alcoholic fatty liver disease , 2008, Gut.
[31] T. Arakawa,et al. Erythrophagocytosis by liver macrophages (Kupffer cells) promotes oxidative stress, inflammation, and fibrosis in a rabbit model of steatohepatitis: implications for the pathogenesis of human nonalcoholic steatohepatitis. , 2007, The American journal of pathology.
[32] O. Cummings,et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.
[33] Renu Virmani,et al. Intraplaque hemorrhage and progression of coronary atheroma. , 2003, The New England journal of medicine.